Lirafit Solution for Injection

Lirafit Solution for Injection

Lirafit is a high-potency, metabolic intervention containing Liraglutide (6 mg/ml), a specialized glucagon-like peptide-1 (GLP-1) receptor agonist. Specifically engineered for the clinical management of type 2 diabetes mellitus and chronic weight management in adults, Lirafit works by targeting the physiological pathways of glucose homeostasis and appetite regulation. Liraglutide acts as a potent biological analog to native GLP-1, binding to and activating the GLP-1 receptor. This targeted biochemical action provides a decisive therapeutic response to stimulate insulin secretion in a glucose-dependent manner, suppress inappropriate glucagon secretion, and delay gastric emptying, effectively stabilizing blood glycemic levels and promoting a sustained feeling of satiety.

Key Features

• Specifically mimics the action of natural incretin hormones to regulate blood sugar.
• Promotes insulin secretion only when blood sugar levels are elevated, reducing the risk of hypoglycemia.
• Targets the brain’s hunger centers to decrease food cravings and promote weight loss.
• Clinically recognized for its potential to reduce the risk of major adverse cardiovascular events in diabetic patients.
• Slows the rate at which food leaves the stomach, leading to a more gradual absorption of glucose.

Key Ingredients

• Liraglutide (6 mg/ml)
• Disodium Phosphate Dihydrate
• Propylene Glycol
• Phenol
• Water for Injection

Precautions

• Must be used strictly under the supervision of an endocrinologist or qualified healthcare professional.
• Not recommended for individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Discontinue use and seek immediate medical attention if you experience persistent, severe abdominal pain.
• While rare when used alone, the risk of low blood sugar increases if used in combination with sulfonylureas or insulin.
• Use with caution in patients with renal impairment; regular monitoring of kidney function may be required.
• Lirafit is contraindicated during pregnancy and lactation; consult your doctor for alternative metabolic therapies.

How to Use

• Administered as a subcutaneous injection in the abdomen, thigh, or upper arm. Do not inject into a vein or muscle.
• Can be administered at any time of day, independent of meals, but should ideally be taken at the same time each day.
• Typically started at a low dose (e.g., 0.6 mg) and increased weekly to minimize gastrointestinal side effects like nausea.
• Ensure the injection pen is primed according to the manufacturer’s instructions before the first use of each new pen.
• Store unused pens in the refrigerator (2°C to 8°C). After first use, the pen can be kept at room temperature or in the refrigerator for up to 30 days.
• Always use a new sterile needle for each injection and dispose of used needles in a sharps container.

Legal Disclaimer: Lirafit Solution for Injection is a prescription-only pharmaceutical product. Individual results regarding blood sugar control and weight loss may vary based on diet, exercise, and metabolic rate. This product is not a substitute for insulin in patients with type 1 diabetes. This information is for educational purposes and is not a substitute for professional medical consultation.